Study summary
The same combination before and after surgery nearly doubled 2-year survival for people who cannot have cisplatin
74.7%event-free at 2 years, vs 39.4% with surgery alone
What was tested
Enfortumab vedotin plus pembrolizumab before and after bladder removal surgery, against surgery alone, for muscle-invasive bladder cancer in people who cannot or chose not to have cisplatin chemotherapy.
What they found
- Event-free survival at 2 years was 74.7% vs 39.4%.
- 2-year survival was 79.7% vs 63.1%.
- No visible cancer at surgery (pathological complete response) in 57.1% vs 8.6%.
What it means
A practice-changing option for the many bladder cancer patients who cannot have cisplatin.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.